Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Shares Issued (2020 - 2025)

Apellis Pharmaceuticals has reported Shares Issued over the past 6 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly results put Shares Issued at -$2.1 million for Q4 2025, up 77.91% from a year ago — trailing twelve months through Dec 2025 was $3.4 million (down 25.75% YoY), and the annual figure for FY2025 was $3.4 million, down 25.75%.
  • Shares Issued for Q4 2025 was -$2.1 million at Apellis Pharmaceuticals, down from $797000.0 in the prior quarter.
  • Over the last five years, Shares Issued for APLS hit a ceiling of $380.1 million in Q1 2022 and a floor of -$377.6 million in Q2 2022.
  • Median Shares Issued over the past 5 years was $2.6 million (2024), compared with a mean of $5.2 million.
  • Peak annual rise in Shares Issued hit 14587.79% in 2022, while the deepest fall reached 42325.73% in 2022.
  • Apellis Pharmaceuticals' Shares Issued stood at $13.0 million in 2021, then plummeted by 2992.96% to -$375.9 million in 2022, then surged by 106.77% to $25.5 million in 2023, then plummeted by 137.24% to -$9.5 million in 2024, then skyrocketed by 77.91% to -$2.1 million in 2025.
  • The last three reported values for Shares Issued were -$2.1 million (Q4 2025), $797000.0 (Q3 2025), and $4.4 million (Q2 2025) per Business Quant data.